๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mianyang
Clinical trial register · China

Clinical Trials in Mianyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Mianyang

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Multicenter Prospective Observational Cohort Study for Digestive Tract Tumor Screening Using Multi-Target Blood and Fecal Biomarkers
NCT07769892Gastrointestinal Cancers
Xijing Hospital
Observational
5,000
Zhaoqing, Xi'an, Jinan, Mianyang, Wuwei, Wuxi
2026-08-10
Recruiting
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596Systemic Lupus Erthematosus
Climb Bio, Inc.
Phase 1/2
30
Mianyang, Beijing
2026-06-30
Recruiting
A Study on Gastrointestinal Cancer Screening Using a Multi-Targeted Combined Detection Model
NCT07712107Gastrointestinal Tumors
Xijing Hospital
Not applicable
10,000
Zhaoqing, Jinan, Mianyang, Wuwei, Wuxi
2026-06-15
Recruiting
IMPACT COPD Cohort (China)
NCT07382986Chronic Obstructive Pulmonary Disease (COPD), Multimorbidities
Beijing Chao Yang Hospital
Observational
10,000
Hebi, Tongliao, Mianyang, Shihezi
2026-02-26
Not yet open
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
NCT07338851Polio, Measles, Rubella, Mumps
China National Biotec Group Company Limited
Observational
600
Suzhou, Handan, Yancheng, Hanzhong, Yuncheng, Mianyang
2026-01-30
Not yet open
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT07381582Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1
15
Beijing, Mianyang
2026-01-01
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06959095Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
981
Changsha, Chengdu, Guangzhou, Hangzhou, Jiangmen, Jiangxi, Mianyang, Qingyuan
2025-06-20
Recruiting
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
NCT06848400Gastric Lesion, Gastritis, Upper Gastrointestinal Bleeding (UGIB), Gastric Dysplasia
Nanfang Hospital, Southern Medical University
Not applicable
482
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Wuxi, Ganzhou, Mianyang
2025-03-03
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042System Lupus Erythematosus
Sinocelltech Ltd.
Phase 1/2
168
Beijing, Changchun, Guangzhou, Hangzhou, Jiujiang, Kunming, Linfen, Mianyang
2025-02
Recruiting
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder
NCT07031544Obsessive - Compulsive Disorder
Shanghai Mental Health Center
Not applicable
60
Guangzhou, Shijiazhuang, Xinxiang, Nanchang, Taiyuan, Mianyang, Shanghai, Tianjin
2024-12-14
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Recruiting
Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
NCT06756139Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug
Air Force Military Medical University, China
Not applicable
88
Haikou, Xi'an, Mianyang
2024-11-01
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Recruiting
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665Asthma
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Recruiting
Clinical Study of Oncolytic Virus in Glioblastoma
NCT07145047Glioblastoma (GBM)
Mianyang Central Hospital
Phase 1/2
20
Mianyang
2023-11-02
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
Recruiting
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
NCT05262010HPV InfectioN, HPV-Related Carcinoma
National Vaccine and Serum Institute, China
Phase 3
13,500
Hechi, Hezhou, Lianyuan, Wuxi, Yongji, Yuncheng, Mianyang, Neijiang
2022-06-04
Recruiting
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
NCT05371353HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
Shanghai Bovax Biotechnology Co., Ltd.
Observational
600
Yangchun, Mianyang
2022-05-14
Active, closed
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
NCT05314023Genital Warts
Merck Sharp & Dohme LLC
Phase 3
1,590
Liuzhou, Louxing District, Guangโ€™an, Mianyang
2022-05-07
Recruiting
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
NCT05027776HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3
1,348
Mianyang
2021-09-15
Recruiting
Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events
NCT04559243Non-valvular Atrial Fibrillation, Embolic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Observational
579
Jinan, Shanghai, Mianyang, Wenzhou
2020-11-12
Active, closed
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
NCT03998254Papillomavirus Infections
Merck Sharp & Dohme LLC
Phase 3
6,000
Guilin, Changzhi, Yuncheng, Mianyang
2019-06-26
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/mianyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Mianyang.

How many clinical trials are recruiting in Mianyang?

18 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mianyang), 22 studies
PhaseStudiesRecruitingShare
Phase 38636.4%
Observational5422.7%
Not applicable4418.2%
Phase 1/23313.6%
Phase 2/3114.5%
Phase EARLY_PHASE1104.5%

Most active sponsors

Lead sponsors with the most studies (Mianyang)
Lead sponsorStudiesRecruiting
GlaxoSmithKline44
Merck Sharp & Dohme LLC20
Shanghai Bovax Biotechnology Co., Ltd.22
Xijing Hospital22
Air Force Military Medical University, China11
AstraZeneca11
Beijing Chao Yang Hospital11
China National Biotec Group Company Limited10
Climb Bio, Inc.11
Lifetech Scientific (Shenzhen) Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.